LYVE-1 Products

Description

LYVE-1 (Lymphatic Vessel Endothelial Receptor 1) is a receptor for the extracellular matrix mucopolysaccharide hyaluronan (HA) and is primarily expressed by lymphatic endothelial cells in addition to the sinusoidal endothelium of the liver and spleen (1-3). HA, also called hyaluronic acid, is a main component of the extracellular matrix and functions largely in cell adhesion, migration, and tissue remodeling (2). HA undergoes a turnover process that involves release from the tissues to the afferent lymph, degradation within the lymph nodes, and removal of fragments by the liver (2,3). LYVE-1, in addition to other lymphatic proteins including VEGFR3, Prox1, and podoplanin, is a common marker for differentiating between the blood and lymphatic systems (2,3). Furthermore, LYVE-1 is closely related to the leukocyte receptor CD44, having ~44% sequence similarity (1-3). Like CD44, the LYVE-1 protein contains an extracellular HA-binding link domain, with N- and C-terminal extensions, located at the end of a glycosylated juxtamembrane domain stalk region, followed by a transmembrane region, and a cytoplasmic tail (1-3). The key features of the HA-binding like molecule are the three disulfide bridges formed by six cysteine residues (1-3). LYVE-1 is synthesized as a protein of 322 amino acids in length with a theoretical molecular weight of 35 kDa, although due to O-glycosylation often appears in SDS-PAGE at a molecular weight ranging from ~60-70 kDa (2,4). The role of HA-binding is further elucidated by the identification of LYVE-1 as a docking receptor for dendritic cells and macrophages, binding their surface HA to control the entry and migration into lymph vessels (1).

LYVE-1 has been an important marker in studies of embryonic and tumor lymphangiogenesis, as many cancers are characterized by early metastasis to the lymph nodes (1-3, 5). One study of five different vascular tumors in infants used immunohistochemical analysis and found positive LYVE-1 expression in infantile hemangioma, tufted angioma, and kaposiform hemangioendothelioma (5). LYVE-1 along with other markers such as GLUT-1, CD31, CD34, Prox-1, and WT-1 can be used to help provide immunohistologic profiles of various tumors and, when used in conjunction with clinical and histopathologic approaches, may offer better overall diagnosis and disease treatment (5).

References

1. Jackson D. G. (2019). Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biology : Journal of the International Society for Matrix Biology. https://doi.org/10.1016/j.matbio.2018.02.001

2. Jackson D. G. (2004). Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. https://doi.org/10.1111/j.1600-0463.2004.apm11207-0811.x

3. Jackson D. G. (2003). The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends in Cardiovascular Medicine. https://doi.org/10.1016/s1050-1738(02)00189-5

4. Unitprot (Q9Y5Y7)

5. Johnson, E. F., Davis, D. M., Tollefson, M. M., Fritchie, K., & Gibson, L. E. (2018). Vascular Tumors in Infants: Case Report and Review of Clinical, Histopathologic, and Immunohistochemical Characteristics of Infantile Hemangioma, Pyogenic Granuloma, Noninvoluting Congenital Hemangioma, Tufted Angioma, and Kaposiform Hemangioendothelioma. The American Journal of Dermatopathology. https://doi.org/10.1097/DAD.0000000000000983

Bioinformatics

Entrez	10894 Human 114332 Mouse
Uniprot	AAH26231 Human AAH26231.1 Human NM_006691 Human NP_006682 Human Q8BHC0 Mouse Q9Y5Y7 Human
Product By Gene ID	10894
Alternate Names	cell surface retention sequence binding protein-1 Cell surface retention sequence-binding protein 1 CRSBP1 CRSBP-1 extracellular link domain containing 1 extracellular link domain-containing 1 Extracellular link domain-containing protein 1 HAR Hyaluronic acid receptor lymphatic vessel endothelial hyaluronan receptor 1 lymphatic vessel endothelial hyaluronic acid receptor 1 LYVE1 LYVE-1 UNQ230/PRO263 XLKD1

Diseases related to LYVE-1

Discover more about diseases related to LYVE-1.

Neoplasms
Neoplasm Metastasis
Malignant Neoplasms
Lymphatic Metastasis
Metastatic Malignant Neoplasm To The Lymph Node
Carcinoma
Cell Invasion
Pathologic Neovascularization
Tumor Angiogenesis
Malignant Paraganglionic Neoplasm
Malignant Neoplasm Of Breast
Mammary Neoplasms
Inflammation
Von Willebrand Disease
Neoplasm Invasiveness
Melanoma
Malignant Squamous Cell Neoplasm
Headache
Tissue Adhesions
Stomach Neoplasms

Pathways for LYVE-1

View related products by pathway and learn more about each of the pathways below.

Lymphangiogenesis
Angiogenesis
Secretion
Pathogenesis
Transport
Cell Adhesion
Cell Migration
Localization
Cell Proliferation
Wound Healing
Cell Growth
Regulation Of Lymphangiogenesis
Tube Formation
Immune Response
Tissue Remodeling
Cell Activation
Vasculogenesis
Cell Maturation
Tissue Development
Cell Motility

Research Areas for LYVE-1

Find related products by research area and learn more about each of the different research areas below.

Endosome Markers
Endothelial Cell Markers
Immunology

PTMs for LYVE-1

Learn more about PTMs related to LYVE-1.

Sulphation
Glycosylation
Acetylation

Bioinformatics Tool for LYVE-1

Discover related pathways, diseases and genes to LYVE-1. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
 

Related LYVE-1 Blog Posts

Check out the latest blog posts on LYVE-1.

Meningeal lymphatics: recent discovery defying the concept of central nervous system 'immune privilege' By Jennifer Sokolowski, MD, PhD. Identification and characterization of meningeal lymphaticsThe recent discovery of a lymphatic system in the meninges surrounding the brain and spinal cord has spurred a surge of int...    Read more.

Read more LYVE-1 related blogs.